SALKA SUSAN R
Known title: Chief Executive OfficerCIK: 0001158584
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
AMN Healthcare Maintains Outperform Rating, Target Raised to $43. Analyst BMO Capital kept an Outperform rating on AMN Healthcare and increased its price target to $43. The company announced a third‑quarter 2026 earnings conference call scheduled for November 5. The stock trades near its $33.96 support level and carries a trailing P/E of 13.4, while analysts’ average target is $36.14.
Transaction History
| MCK | ▼ Sell | Open Market | 1 | $541 | 5/13/2024 | View on chart |
| MCK | ▼ Sell | Open Market | 606 | $338K | 5/10/2024 | View on chart |
| MCK | ▼ Sell | Open Market | 4 | $2K | 5/10/2024 | View on chart |
| MCK | ▼ Sell | Gift | 1,000 | $0 | 2/6/2023 | View on chart |
| MCK | ▼ Sell | Gift | 1,000 | $0 | 11/8/2022 | View on chart |
| AMN | ▲ Buy | Option Exercise | 10,136 | $0 | 9/20/2022 | View on chart |
| AMN | ▼ Sell | Tax Withholding | 3,989 | $428K | 9/20/2022 | View on chart |
| MCK | ▲ Buy | Grant | 606 | $0 | 7/22/2022 | View on chart |
| AMN | ▼ Sell | Open Market | 2,516 | $272K | 2/28/2022 | View on chart |
| AMN | ▼ Sell | Open Market | 10,031 | $1.1M | 2/28/2022 | View on chart |
| AMN | ▼ Sell | Open Market | 7,838 | $834K | 2/28/2022 | View on chart |
| AMN | ▼ Sell | Open Market | 2,090 | $221K | 2/28/2022 | View on chart |
| AMN | ▼ Sell | Open Market | 200 | $21K | 2/22/2022 | View on chart |
| AMN | ▼ Sell | Open Market | 1,013 | $106K | 2/22/2022 | View on chart |
| AMN | ▼ Sell | Open Market | 311 | $33K | 2/22/2022 | View on chart |
| AMN | ▼ Sell | Open Market | 1,076 | $114K | 2/22/2022 | View on chart |
| AMN | ▼ Sell | Open Market | 100 | $11K | 2/22/2022 | View on chart |
| AMN | ▲ Buy | Grant | 41,510 | $0 | 2/17/2022 | View on chart |
| AMN | ▼ Sell | Tax Withholding | 16,335 | $1.6M | 2/17/2022 | View on chart |
| AMN | ▼ Sell | Open Market | 1,200 | $111K | 1/24/2022 | View on chart |
| AMN | ▼ Sell | Open Market | 3,200 | $298K | 1/24/2022 | View on chart |
| AMN | ▼ Sell | Open Market | 4,585 | $434K | 1/24/2022 | View on chart |
| AMN | ▼ Sell | Open Market | 3,045 | $290K | 1/24/2022 | View on chart |
| AMN | ▼ Sell | Open Market | 3,373 | $324K | 1/24/2022 | View on chart |
| AMN | ▼ Sell | Open Market | 1,588 | $167K | 1/10/2022 | View on chart |
| AMN | ▼ Sell | Open Market | 1,400 | $149K | 1/10/2022 | View on chart |
| AMN | ▼ Sell | Open Market | 2,000 | $215K | 1/10/2022 | View on chart |
| AMN | ▼ Sell | Open Market | 2,100 | $229K | 1/10/2022 | View on chart |
| AMN | ▼ Sell | Open Market | 1,900 | $209K | 1/10/2022 | View on chart |
| AMN | ▼ Sell | Open Market | 1,200 | $133K | 1/10/2022 | View on chart |
| AMN | ▼ Sell | Open Market | 2,510 | $281K | 1/10/2022 | View on chart |
| AMN | ▼ Sell | Open Market | 1,316 | $149K | 1/10/2022 | View on chart |
| AMN | ▼ Sell | Open Market | 295 | $34K | 1/10/2022 | View on chart |
| AMN | ▲ Buy | Grant | 23,450 | $0 | 1/4/2022 | View on chart |
| AMN | ▼ Sell | Tax Withholding | 8,047 | $972K | 1/4/2022 | View on chart |
| AMN | ▼ Sell | Open Market | 492 | $60K | 12/23/2021 | View on chart |
| AMN | ▼ Sell | Open Market | 8,924 | $1.1M | 12/23/2021 | View on chart |
| AMN | ▼ Sell | Open Market | 3,238 | $387K | 12/23/2021 | View on chart |
| AMN | ▲ Buy | Option Exercise | 7,543 | $0 | 12/17/2021 | View on chart |
| AMN | ▼ Sell | Tax Withholding | 2,969 | $338K | 12/17/2021 | View on chart |
| AMN | ▲ Buy | Option Exercise | 6,476 | $0 | 12/16/2021 | View on chart |
| AMN | ▼ Sell | Tax Withholding | 2,549 | $292K | 12/16/2021 | View on chart |
| AMN | ▲ Buy | Option Exercise | 6,849 | $0 | 12/16/2021 | View on chart |
| AMN | ▼ Sell | Tax Withholding | 2,696 | $308K | 12/16/2021 | View on chart |
| AMN | ▼ Sell | Gift | 6,247 | $0 | 5/13/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
McKesson Re-Rated on M&A Momentum Amid Strong Performance
McKesson shares have risen while the broader market fell, driven by renewed analyst interest in the company's increased M&A efforts. This positive sentiment aligns with recent recognition from financial commentators who view the healthcare stock as a strong performer. The stock's strength is further supported by a high RSI, indicating significant recent buying pressure.
McKesson Re-Rated on M&A Momentum Amid Strong Performance. McKesson shares have risen while the broader market fell, driven by renewed analyst interest in the company's increased M&A efforts. This positive sentiment aligns with recent recognition from financial commentators who view the healthcare stock as a strong performer. The stock's strength is further supported by a high RSI, indicating significant recent buying pressure.